EU Explains Plans To Speed Up Variant Vaccine Approvals
New EMA Expert Group Will Probe AZ Vaccine Blood Clot Issue
The EU institutions are taking steps to preserve the effectiveness of existing vaccines in the face of mutations in the SARS-CoV-2 virus.
You may also be interested in...
The French authorities believe that the “heterologous prime-boost” approach is justified in the case of people aged under 55 years who are due to receive their second dose of the AZ COVID-19 vaccine.
Senior members of three key regulatory and health bodies this week gave their assessments of the protection that existing COVID-19 vaccines may offer against future strains of the virus, and the requirements for developing and assessing modified vaccines.
The EMA’s conclusions are in line with those of the UK regulator and the World Health Organization, but EU countries’ stop-start decisions will have done nothing to boost the public’s trust in the vaccine.